53 related articles for article (PubMed ID: 34816394)
41. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
[TBL] [Abstract][Full Text] [Related]
42. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
Mezquita L; Varga A; Planchard D
Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
[TBL] [Abstract][Full Text] [Related]
43. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
Soejima K; Yasuda H; Hirano T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
[TBL] [Abstract][Full Text] [Related]
44. Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer.
Gandhi S; Roy I
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242697
[TBL] [Abstract][Full Text] [Related]
45. Inhaled Medicines for Targeting Non-Small Cell Lung Cancer.
Al Khatib AO; El-Tanani M; Al-Obaidi H
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140117
[TBL] [Abstract][Full Text] [Related]
46. Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation.
Sawant SS; Patil SM; Shukla SK; Kulkarni NS; Gupta V; Kunda NK
Drug Deliv Transl Res; 2022 Oct; 12(10):2474-2487. PubMed ID: 34816394
[TBL] [Abstract][Full Text] [Related]
47. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
Zhang Q; Liu H; Yang J
Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717
[TBL] [Abstract][Full Text] [Related]
48. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
49. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
50. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
51. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
